ReviewDigestive diseases and sciences2017
Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature.
Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease.Inflammopharmacology · 2019Trial
- TR4-triggered recruitment of suppressive rhizomicrobiome enhances Fusarium wilt resistance in banana.The New phytologist · 2026Article
- Fecal microbiota transplantation in pigs: current status and future perspective.Animal microbiome · 2025Review
- Article
- Microbiota transplantation.Heliyon · 2024Review
- Fecal microbiota transplantation stimulates type 2 and tolerogenic immune responses in a mouse model.Anaerobe · 2024Article
- The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies.International journal of hepatology · 2024Review
- From microbes to medicine: harnessing the gut microbiota to combat prostate cancer.Microbial cell (Graz, Austria) · 2024Article
- Comparison of the effect of autoclaved and non-autoclaved live soil exposure on the mouse immune system : Effect of soil exposure on immune system.BMC immunology · 2023Article
- Catestatin: Antimicrobial Functions and Potential Therapeutics.Pharmaceutics · 2023Review
- The Black Box Orchestra of Gut Bacteria and Bile Acids: Who Is the Conductor?International journal of molecular sciences · 2023Review
- Anti-cancer activity of human gastrointestinal bacteria.Medical oncology (Northwood, London, England) · 2022Review
- Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives.World journal of gastroenterology · 2022Review
- Effect of inactivated nature-derived microbial composition on mouse immune system.Immunity, inflammation and disease · 2022Article
- The Combination of Phages and Faecal Microbiota Transplantation Can Effectively Treat Mouse Colitis Caused byFrontiers in microbiology · 2022Article
- Fecal microbiota transplantation - where are we?Croatian medical journal · 2021Article
- Fecal Microbiota Transplantation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review.Journal of personalized medicine · 2021Review
- The Association of Gut Microbiota and Treg Dysfunction in Autoimmune Diseases.Advances in experimental medicine and biology · 2021Article
- Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
- Mini-Review: Human Microbiome and Rheumatic Diseases.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsFecal microbial transplantation (FMT) is an established successful treatment modality for recurrent Clostridium difficile infection (CDI). The safety profile and potential therapeutic advantages of FMT for diseases associated with dysbiosis and immune dysfunction have led to many publications, mainly case series, and while many studies and reviews have been published on the use of FMT for inflammatory bowel disease (IBD), its potential use for other disease conditions has not been thoroughly reviewed. The aim of this review was to investigate the evidence surrounding the use of FMT in conditions other than IBD and CDI.
methodsA PubMed search was performed using the terms "Fecal microbiota transplantation" OR "FMT" OR "Bacteriotherapy."
resultsA total of 26 articles describing the use of FMT in a variety of both intra-and extraintestinal disease conditions including gastrointestinal, hematologic, neurologic, metabolic, infectious, and autoimmune disorders have been included in this review and have demonstrated some positive results. The studies included were case reports, case series, controlled trials, and cohort studies.
conclusionsThe findings of these studies demonstrate that FMT, particularly in conditions associated with gastrointestinal dysbiosis, shows promise to provide another effective tool in the therapeutic armament of the practicing physician. FMT was found to be possibly effective in various diseases, mostly associated with enteric dysbiosis or with immune dysfunction. Randomized clinical studies on large populations should be performed to explore the effectiveness of this therapy, and basic research studies should be designed to gain understanding of the mechanisms through which impact these disorders.
Indexed as
Identifiers
28315032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.